ADC Development Services Targeting LAMP1

Creative Biolabs is a leading biotechnology company which has the expertise and ability to provide integrated antibody-drug conjugates (ADCs) service for customers worldwide. With sophisticated equipment, advanced technologies and highly experienced staffs, we are able to assist you with the complete ADCs development against different antigens, such as the LAMP1. Creative Biolabs is happy to streamline the platform processes or work with you to design a process that meets your specific needs and accelerate your ADCs drug research and development projects.

Introduction of LAMP1

LAMP-1 (lysosomal-associated membrane protein 1), also known as CD107a, is a type I membrane glycoprotein encoded by the LAMP1 gene that located at the long arm (q) of chromosome 13 in human. LAMP-1 is found in a variety of normal cell types and involved in the production of selectins and carbohydrate ligands. It is composed of a large, highly glycosylated end with N-linked carbon chains, a short C-terminal tail exposed to the cytoplasm and an extracytoplasmic region contains a hinge-like structure. LAMP-1 is regarded as a marker of degranulation on lymphocytes and may also function in tumor cell differentiation and metastasis. It is highly expressed on many solid tumors cells, such as colon carcinoma, human fibrosarcoma, pancreatic adenocarcinoma and melanoma, and has been found associated with tumor metastatic potential. Thus, LAMP1 is considered as a potential target in the cancer immunotherapy.

Fig.1 Model of lysosomal membrane proteins and the glycoprotein coat. (Wilke, 2012)

Anti-LAMP1 ADC in Solid Tumors

LAMP1 is highly expressed on a number of solid tumors while has very limited expression in the cell surface of normal tissues. Thus, it is a potential target being used in the ADC design for the solid tumors therapy. For example, SAR428926 is an ADC comprising an anti-LAMP1 humanized monoclonal antibody linked to the maytansinoid derivative DM4 (a tubulin interfering molecule) through a cleavable SPDB linker.

During the preclinical studies, SAR428926 ADC can specifically bind to the LAMP1 at the surface of tumor cells and internalize rapidly into tumor cells. It showed outstanding antitumor activity with complete regressions. In addition, this ADC has been promoted to clinical trial in patients with solid tumors to assess its outcome. Currently, SAR428926 is investigated in the clinical phase II.

Fig.2 Structure of SAR428926 ADC. (Jain, 2015)

What Can We Do for You?

Creative Biolabs is pioneering in the development of bio-conjugates. We aim to provide top-quality ADCs development services against all kinds of biomarkers including the LAMP1 for global customers. Our team uses improved technology platforms that can increase the success rate of your novel drug discovery project. These technology platforms include ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis. If you have any special requirements in ADCs construction, please feel free to contact us. We are looking forward to working together with your attractive projects.

References

1. Wilke, S.; et al. Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycocalyx. BMC biology. 2012, 10(1): 62.
2. Jain, N.; et al. Current ADC linker chemistry. Pharmaceutical research. 2015, 32(11): 3526-3540.

For Research Use Only. NOT FOR CLINICAL USE.